Spyre exchanges 90,992 Series A Preferred shares for 3.64M common shares

Spyre Therapeutics, Inc.

90,992 shares of Series A Non-Voting Convertible Preferred Stock exchanged for 3,639,680 shares of common stock.
Exchange closed April 25, 2024; common shares outstanding post-exchange: 40,279,414.
Exemption from registration relied on Section 3(a)(9) of Securities Act; no commission paid.
Counterparty is Fairmount Healthcare Fund II L.P.; conversion ratio based on existing conversion terms.
Following exchange, 346,045 Series A Preferred and 271,625 Series B Preferred remain outstanding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.